

SWISS BIOTECH DAY 2023

© Swiss Biotech Association

April 24-25, 2023
Congress Center Basel

Organized by:




bamconn

BIOCOM®

Conference program at a glance

Monday, April 24, 2023

11:00-12:00	Swiss Biotech Association General Assembly	Room Sydney
12:00-12:45	Press Conference (media only)	Room Rio
12:00-18:30	Exhibition throughout the day	Foyer 2 nd floor and Room Singapore page 34
	Poster presentations throughout the day	Room Singapore page 39
12:00-19:00	Global Village throughout the day	Room San Francisco page 14
12:00-19:00	Partnering throughout the day	Room San Francisco page 3
13:00-14:30	Plenary Session I	Room Montreal page 4
14:30-15:00	Coffee Break	
from 14:45	Parallel Tracks	
	Emerging Biotech Companies Room Sydney page 5	Clinical Stage Biotech Companies Room Rio page 6
	Panel Discussions 1-4 Room Montreal page 8	Advanced Biotech Companies Room Osaka page 7
	Panel Discussions 5-8 Room Samarkand page 10	Panel Discussions 9-12 Marriott Hotel page 12
14:45-17:30	Round Table Discussions	San Francisco page 15
17:30-18:15	Venture Leaders Pitch	Room Singapore page 6
18:00-19:00	International Reception	Room San Francisco
18:30-21:00	Evening Reception	Foyer 2 nd floor 



Free WiFi

SSID: Free Messe Basel
Free SMS-Login
(one Login for each device)



Twitter

#swissbiotechday




LinkedIn

#swissbiotechday

Tuesday, April 25, 2023

07:30	Registration opens	Entrance
08:00-16:00	Partnering throughout the day	Room San Francisco page 3
09:00-16:00	Exhibition throughout the day	Foyer 2 nd floor and Room Singapore page 34
	Poster presentations throughout the day	Room Singapore page 39
09:00-16:00	Global Village throughout the day	Room San Francisco page 20
09:30-11:30	Plenary Session II	Room Montreal page 18
11:30-12:30	Lunch	Foyer 2 nd and 3 rd floor 
11:30-15:45	Round Table Discussions	San Francisco page 22
11:45-13:15	Swiss Biotech Association Diagnostic Chapter	Room Singapore page 19
from 12:30	Parallel Tracks	
	Emerging Biotech Companies Room Sydney page 23	Clinical Stage Biotech Companies Room Rio page 24
	Panel Discussions 13-16 Room Montreal page 26	Advanced Biotech Companies Room Osaka page 25
	Panel Discussions 17-20 Room Samarkand page 28	Panel Discussions 21-24 Marriott Hotel page 30
14:15-14:45	Coffee Break	
16:00-18:00	Evening Reception	Foyer 2 nd floor
16:30	Draw of three prize winners	Foyer 2 nd floor

The pre-scheduled one-to-one meetings take place as follows:

Please check your individual meeting schedule for times and locations of your confirmed meetings.
Need help? Please see the Partnering Help Desk in room San Francisco.
<https://www.hellopartnering.com/login/index/SBD23>
presented by 



25 years of major Swiss biotech innovations

Most of these highlights were achieved in international collaborations and benefit patients around the world. They do not represent a comprehensive list but rather a selection that emphasizes the diversity of modalities that have been developed over time and the broad range of medical needs they help to address.

How to play

- Collect the 25 stickers of major Swiss biotech innovations from the last 25 years at any of the exhibitors' booths
- Glue the stickers on the right name on the inside of the collection sheet (available at the reception and the booth #1 and #66).
- Trade your multiple stickers e.g. during your 1:1 meetings or networking breaks. If you miss only one sticker, come to the Swiss Biotech Association or BIOCOT booth (#1 and #66), and we will help you to complete your sheet
- Once completed, bring this sheet to the Swiss Biotech Association booth #1
- The winners of the three prizes will be drawn from all participants who fully complete the collection sheet.

You can win

- Glacier Express ride
- Hot air balloon flight
- Lucerne and boat tour

Plenary Session I

Room Montreal

Moderation: Monika Jones

13:00 Opening

Monika Jones, Moderation

Welcome Address

Michael Altorfer, CEO, Swiss Biotech Association

13:10 Celebrating 25 years of biotech innovation:

From treating symptoms towards precision medicine

Introduction: Patrick Amstutz, CEO Molecular Partners, President of the Swiss Biotech Association

Moderation: Michael Hengartner, President of the ETH Board

Martine Clozel, co-Founder and CSO, Idorsia

Markus Goebel, ex Novartis Venture Fund











Dominik Escher, Managing Partner, Pureos Bioventures

Lutz Hegemann, President Global Health & Sustainability, Novartis

Andreas Plückthun, Professor of Biochemistry, University of Zurich

Emerging Biotech Companies








Moderation: Dominik Escher & Anne Grahl, Pureos Bioventures Presented by 

Time	Company	Room Sydney
14:45	Pureos Bioventures	
15:00	Vandria	
15:15	Noema Pharma	
15:30	FimmCyte	
15:45	Orion Biotechnology	
16:00	Peptone	
16:15	InCephalo	
16:30	FoRx	
16:45	LimmaTech Biologics	
17:00	Asterivir	

See all information on the presenting companies here →



Clinical Stage Companies

Time	Company	Room Rio
15:00	AC BioScience	
15:15	GeNeuro	
15:30	Immunophotonics Switzerland	
15:45	Molecular Partners	
16:00	Endogena Therapeutics	
16:15	Cellis	
16:30	ARENSIA	

Presented by



Venture Leaders Pitch

Room Singapore

Discover the Venture Leaders Biotech opportunities

Successful Venture Leaders alumni Ulf Grawunder will share his experience in building and selling NBE Therapeutics, a 1.1 bn exit, followed by pitches of selected biotech startups.

Moderation: Jordi Montserrat, Co-Founder and Managing Partner, Venturelab

17:30	Venture Leaders Biotech introduction	
17:35	Affivant Sciences GmbH	17:50 Limula SA
17:38	metaLead Therapeutics	17:53 Tandem Therapeutics
17:41	Navignostics AG	17:56 ND Biosciences SA
17:44	ASTRA Therapeutics	17:59 Invasight AG
17:47	SURI BioTech GmbH	18:02 Mosanna Therapeutics AG
18:05	Voting for team captain selection and Debiopharm closing address	

Advanced Biotech Companies

Presented by



Time	Company	Room Osaka
14:45	Stücki Park	
15:00	Bio-Techne	
15:15	AAC Infotray	
15:30	DyNABind	
15:45	Nuvisan	
16:00	Johnson & Johnson	
16:15	Lexogen	
16:30	Medicilon	
16:45	Addex Therapeutics	
17:00	Sino Biological	
17:15	Cambrex	
17:30	Catenion	
17:45	Springer-Verlag	
18:00	Wuxi AppTec	
18:15	Pattern-Computer	

See all information on the presenting companies here →



Presented by

**14:45-15:30 Panel 1**

Room Montreal

Breaking Boundaries: The Emergence of Regenerative Medicine, Digital Technologies and Genomics

Focusing on scientific opportunities, this panel discussion is looking to exchange ideas between leading biotech nations, foster greater collaboration across the entire ecosystem and highlight some of the most exciting current and future developments in addressing unmet diseases.

Moderation: *Nicholas Franco, Former EVP and Chief Business Development Officer Johnson & Johnson*

Panelists:

Michael May, President and Chief Executive Officer, Centre for Commercialization of Regenerative Medicine

Rob Annan, President and Chief Executive Officer, Genomics Canada

Raphaëlle Luisier, Group Leader at Idiap Research Institute, Swiss Institute of Bioinformatics

Avaleigh Milne, Head of Business Development for Pharma Research and Early Development at Roche

Presented by

**15:45-16:30 Panel 2**

Room Montreal

Powering Precision Medicine Using Multi Level Data

Despite revealing tremendous insights into the cause and underlying mechanism of complex diseases such as cancer, cardiovascular disorders, neuropathological diseases, rare diseases etc., genomics alone often fails to identify important biomarkers for best therapy decisions. At this panel, we will explore with leading Swiss digital life science companies the advantages, promises but also obstacles of utilizing multi-molecular level data to advance precision medicine.

Moderation: *Abdullah Kahraman, Lecturer and Group Leader in Data Science in Life Sciences, FHNW Life Sciences*

Panelists:

Moritz Kirschmann, Group Leader AI for Life Sciences, CSEM

Sarah Carl, Director of Data Science, Scaillyte

Axel Martinelli, Head of Biology, BigOmics Analytics

Guillaume Cettou, Senior Director Business Development BioPharma, Sophia Genetics

Presented by

**16:45-17:30 Panel 3**

Room Montreal

Opportunities of digitalization in the healthcare system, relevance and benefits of data collection from citizens (incl. healthy citizens)

Our expert panelists will discuss opportunities of digitalization for the Swiss healthcare system. Listen to representatives of the patient, hospital, pharma and tech. sectors. According to digitalswitzerland's published study based on a population survey, citizens are willing to share their data digitally, given it has clear benefits such as usability, improved diagnosis and treatments, etc. Collecting data will ensure transition from a "sick care" to a "healthcare" system.

Moderation: *Jade Sternberg, Project Lead Digital Health, digitalswitzerland*

Panelists:

Sebastiano Caprara, Head Digital Medicine Unit, Balgrist Hospital

René P. Buholzer, CEO and Delegate of the Board, Interpharma

Steven Bourke, CEO Founder, Personal Pulse

Chantal Stäubli, Chief Business Innovation and Transformation Officer, Netcetera

Presented by

**17:45-18:30 Panel 4**

Room Montreal

The four dimensions of Switzerland's contribution to Health Care systems around the world

- Guarantor of reliable life sciences supply chains
- Promoter of multinational regulatory networks
- Supporter of global HC initiatives
- Driver of international research programs

At this panel we will discuss with a group of industry representatives, researchers and NGOs how Switzerland contributes to the strengthening of health care systems around the world.

Moderation: *Monika Jones*

Panelists:

André Guedel, Head Life Science BD, KPMG


Isabel Mestres, CEO, C/Can, City Cancer Challenge

Lutz Hegemann, President Global Health & Sustainability, Novartis

Peter Droc, Business Head for Lonza's Drug Product Services Business, Lonza AG

Kaspar Wyss, Deputy Director, Swiss Tropical and Public Health Institute

Presented by

**14:45 - 15:30 Panel 5**

Room Samarkand

How can Swiss biotech remain competitive in a challenging environment for early stage financing and partnering?

After record years of capital investments into biotech companies during the Covid pandemic, the global investment climate for biotech companies has reversed in 2022. The Swiss Venture Capital Report 2023 revealed a sharp downturn in biotech investments (back to the average level of 2017-2019), while other sectors improved and reached record highs. This panel will discuss the implications, the wider industry context and how the vibrant Swiss innovation ecosystem can best compete on a global stage, with perspectives from VC, pharma, biotech, Venturelab and the panel host, Swiss HLG.

Moderation: Sarah Holland, President, Swiss HLG

Panelists:

Jordi Montserrat, Co-Founder and Managing Partner, Venturelab

Veronica Gambillara Fonck, Partner, Pureos Bioventures

Michael Huebner, Director Early Innovation Partnering, Johnson & Johnson

Alexander Breidenbach, CDO/CBO, ACM Biosciences

Presented by

**15:45 - 16:30 Panel 6**

Room Samarkand

Cluster Switzerland: New Ways and Opportunities

Panelists from the newly formed Swiss Biotech Association Legal Tax & Accounting Chapter will share some key points of the Swiss framework conditions and more efficient ways to achieve the goals of biotech companies. Active participation of the audience is welcome.

Moderation: Matthias Staehelin, Lead Partner Life Sciences, VISCHER AG

Panelists:

Dieter Gericke, Head Corporate / M&A, Co-Head Healthcare, Homburger AG

Bettina Ernst, Vice-Chairperson SBA, Innosuisse Innovation Council

Frederik Schmachtenberg, Partner EY Life Sciences, Ernst & Young Ltd

Maurus Winzap, Partner, Head of Tax, Walder Wyss Ltd

Presented by

**16:45 - 17:30 Panel 7**

Room Samarkand

Trends in Process Intensification for Biomanufacturing

Over the last decade, methods and equipment of process intensification have been developed for biopharmaceutical processes. In this panel led by Thermo Fisher Scientific, we will review the recent advances in process intensification development for biologics manufacturing with several process development experts. We will exchange on the successes and challenges encountered during the development and technology transfer of intensified processes through a Q & A session.

Moderation: Arnaud Desponds, Sr. Manager, Business Management | Biologics, Thermo Fisher Scientific

Panelists:

Thomas Villiger, Professor of Bioprocess Technology, University of Applied Sciences and Arts Northwestern Switzerland FHNW, Institute of Pharma Technology

Preeti Phanse, BPS Upstream Labs SME | Biologics, Thermo Fisher Scientific

Edwige Dormond, Director, MSAT | Biologics, Thermo Fisher Scientific

Presented by

**17:45 - 18:30 Panel 8**

Room Samarkand

Swiss Biotech Association – Industrial Biotechnology Chapter. Solutions for global industrial challenges

The panel will demonstrate how biotechnology generates effective solutions to global industrial and environmental challenges.

The session supports the launch of the Swiss Biotech – Industrial Biotech Chapter. This will foster collaboration between industry participants, accelerate commercially-relevant innovation and promote the industrial biotech industry in Switzerland.

Moderation: David Lyon, Strategy Director, Pheida AG

Panelists:

Vivek Dogra, Venture Partner, European Circular Bioeconomy Fund (ECBF)

Susanne Heldmaier, Strategic Lead of Basic Research & Technical Innovation, Mibelle Group

Peter van Gelderen, General Partner, Icos Capital

Erika S. Georget, Managing Director, Eridia (a Bühler and Zeta company)

Presented by

**14:45-15:30 Panel 9**

Marriott Hotel

Scaling for Growth: How to succeed in navigating key milestones such as funding, IPO, operational setup, and launch, which will define your future

This panel provides a cross-functional perspective from biotech industry leaders who will share their experiences in navigating key growth milestones along their journey. You will hear leading biotech C-suite executives and investors explaining how they addressed key strategic questions such as:

How do I execute on the science and raise sufficient funds? | What are criteria investors value to make funding decisions? | What are the attributes of a viable business model and key partnerships needed? | What are the key commercial, regulatory, and quality decisions needed to support our first launch? | What is our commercial and operational model to support growth?

Moderation: Elisabeth Aloy, Life Sciences Strategy Partner, Deloitte

Panelists:

Melanie Rolli, CEO of Helsinn and Board Member

Boris Javelle, CFO, early stage Biotech

Peter Vanoverveld, co-CEO of SmartReporting

Klaus Breiner, Founding partner of Pureos

Presented by

**15:45-16:30 Panel 10**

Marriott Hotel

Set up for success: what have the past 25 years taught us about the future of biopharmaceutical innovation?

The pace of change over the last 25 years has been tremendous. Scientific progress in genetics, drug discovery, novel therapeutics and diagnostics have transformed the outlook for millions of patients with serious diseases. This panel discussion spotlights how innovations across biopharma and academia have contributed to many signature achievements over this period and anticipates how these success stories will inform future breakthroughs.

Moderation: James Drew, Consultant, Citeline

Panelists:

Andreas Wallnoefer, Partner at Jeito Capital

Burkhard Ludwig, Head Translational Cardioimmunology, University Heart Center Zurich

Ulf Grawunder, Swiss Biotech Association Board Member, founder of NBE Therapeutics

Hanns-Christian Mahler, CEO at ten23 health

Presented by

**16:45-17:30 Panel 11**

Marriott Hotel

Integrated evidence plan (IEP), an accelerator for drug development and market access

An IEP catalogs all existing and planned evidence, and seeks to identify unmet evidence requirements, dependencies, and common themes across different categories of evidence. Join our panel-discussion with biotech and IQVIA expert-panelists to learn more about IEP and why you should integrate it into your clinical development early on to draw more value from your data. IEP also supports with maximizing the value of your asset and optimizing access to patients. Our panel draws from the broad experience of leveraging an IEP in biotech's, we will include early stage biotech start up founders, a biotech CEO with a first product launch, an ISPOR board member discussing the recommendations for evidence gathering and IEPs as well as IQVIA experts that can give examples of how IEPs are leveraged across the industry.

Moderation: Jennifer Cain Birkmose, Sr. Principal Strategy Consulting, IQVIA AG

Panelists:

Zuzanna Angehrn, PhD, Principal, Real World Solutions, IQVIA AG

Djordje Filipovic, CEO, AB2 Bio Ltd

Sezai Taskin, Co-Founder, CEO, Moonlight AI

Marlene Gyldmark, Global Head HEOR & Epidemiology, Idorsia Pharmaceuticals Ltd

Presented by

**17:45-18:30 Panel 12**

Marriott Hotel

RNA Therapeutics: The short, the long and genome editing

RNA Therapeutics became broadly known through the mRNA-based vaccines to combat the Covid-19 pandemic. Besides vaccines, RNA-based drugs can be used for a wide variety of medical applications such as short RNA drugs to suppress or alter gene expression, long RNAs to induce therapeutic protein production and RNAs are also an essential component of many genome engineering technologies such as CRISPR/Cas. Such therapeutic approaches will be discussed during the panel.

Moderation: Dominik Theler, Scientific Officer, NCCR RNA & Disease: University of Bern & ETH Zurich

Panelists:

Jacob Corn, Full Professor, ETH Zurich

Markus Stoffel, Full Professor, ETH Zurich

Klaas Zuideveld, CEO, Versameb

Global Village

12:00 - 19:00 Global Village

Room San Francisco

Presented by



Supported by

Welcome to the Global Village at the Swiss Biotech Day 2023

The Global Village platform is a dedicated offering for national and regional foreign biotech clusters which intend to develop and strengthen long-term and sustainable business ties and collaborations with various stakeholders of the Swiss biotech ecosystem. It is an integral part of the Swiss Biotech Day as the anchor event for the Global Village platform.

International delegations who participate in the Global Village platform benefit from several tailor-made opportunities in addition to the classical offerings of the Swiss Biotech Day: they present themselves through dedicated delegation booths in the Global Village area of the Swiss Biotech Day, they participate in a roundtable discussion tailor-made for each delegation and they will be part of the international reception for foreign delegations. In addition, delegations may participate in dedicated site visits of selected biotech hotspots in Switzerland directly after the Swiss Biotech Day.

Typically, delegations include a cross-section of their respective biotech hub including C-level entrepreneurs, venture builders and investors, researchers and academics, leading hospital representatives, clinical investigators and CROs, government bodies and economic development agencies to representatives of incubators and accelerators.

The Global Village Platform is presented by the Swiss Biotech Association and Switzerland Global Enterprise.

All participants of the Swiss Biotech Day are welcome to explore the Global Village booths and engage with delegation members in the Global Village area of the Swiss Biotech Day.



Switzerland Global Enterprise

Switzerland Global Enterprise (S-GE) is the official Swiss consultancy, promotion and platform organization for export and investment promotion. As a non-profit organization, we provide a public service for our clients on behalf of the Swiss Confederation and cantons since 1927. With our partners at home and abroad, we support Swiss SMEs in their international business and help innovative foreign companies with potential that are interested in settling in Switzerland.

Round Table Discussions

Please join us for roundtable discussions, aiming to facilitate partnerships and connect international representatives with the Swiss biotech industry for research, corporate collaborations, policy-making and investments.

Time	Country	Room San Francisco
14:45-15:15	Delegation of India	
15:30-16:00	Delegation of Brazil	
16:15-16:45	Delegation of Saxony	
17:00-17:30	Delegation of Oregon	

Global Village

Presented by

Swiss-Indian Chamber of Commerce

Delegation of India

Swiss-Indian Chamber of Commerce

SICC is a binational, private, non-profit association. It is a leading platform for cross-border business, a major player in promoting economic relations between India and Switzerland, who cooperates with all public and private institutions pursuing similar goals.

The SICC Board of Directors includes representatives of companies that are actively committed to deepening Swiss-Indian economic relations.

SICC has offices in Zurich, Switzerland and Mumbai, India.

Participants: Swiss-Indian Chamber of Commerce, K&S Partners, Swati Spentose Pvt Ltd, Haselmeier GmbH, CUTISS AG, Guidance, Government of Tamil Nadu, Telluris Biotech India Pvt. Ltd, Exsegen Research, Ancillarie

Presented by



Delegation of Brazil

Sindusfarma

Founded 90 years ago, in 1933, the Pharmaceutical Industry Syndicate, Sindusfarma, the largest representative entity of the pharmaceutical industry installed in Brazil, currently brings together 548 national and international companies of all sizes and specialties, in addition to suppliers and service providers of the pharmaceutical production chain, which account for more than 95% of the drug market in Brazil.

Participants: Abiquif, Blau Farmacêutica, Geolab, ICL, Inovatie, Intrials, Magna Sourcing, SPLaw, Sindusfarma, INPI Instituto Nacional da Propriedade Industrial ANVISA Brazilian Health Regulatory Agency



Presented by

GTAI

Delegation of Saxony

Airea – The Airport Region in Central Germany

Airea – The Airport Region in Central Germany is one of the top addresses for life sciences. With its diversified cluster consisting of the health care industry, biotech, medtech, the pharmaceutical industry as well as pharmaceutical & medical logistics, the region unites a broad, multifaceted spectrum of efficient & effective stakeholders from business & science while also covering the entire value creation chain: from R&D, production, marketing, logistics & service.

Participants: AIREA – The Airport Region in Central Germany, IMG (Investitions- und Marketinggesellschaft Sachsen-Anhalt), biosaxony, Wirtschaftsförderung Sachsen WFS, Fraunhofer IZI

Presented by



Delegation of Oregon

Business Oregon

Business Oregon is the State of Oregon's economic development agency. Bioscience is one of Oregon's leading Target Industries and has become an emerging, competitive segment of Oregon's economy. Due to a recent influx of firms, and expansions, like Twist Bioscience and Genentech (a Roche subsidiary) which together will create over 700 new jobs, Oregon's bio community is growing faster and gaining more market share vs. many other U.S. states. With 1,480 establishments, Oregon's Bio market produced \$15.7 billion (2020) in total economic output, and nearly \$1 billion (2019) in pharmaceuticals, medicine, and medical equipment.

Participants: Business Oregon, Rewire Neuro, Oregon Bioscience Association, Aronora, InVivo Biosystems, UbIVac

Plenary Session II

Room Montreal

*Moderation: Monika Jones***09:30 Welcome Address**

Michael Altorfer, CEO, Swiss Biotech Association

09:40 Global trends in biopharmaceutical innovation and outlook

Alexandra Zemp, Partner, McKinsey

Isma Hachi, Director Emerging BioPharma, IQVIA

Daniel Chancellor, Consulting Director, Citeline

Frederik Schmachtenberg, Partner, EY

10:10 Swiss Biotech Report 2023

Frederik Schmachtenberg, Partner, Global Life Sciences Lead for Financial Accounting Advisory Services, EY

10:30 Keynote

George Scangos, member of the Board of Directors at Vir Biotechnology and former CEO of Biogen Inc.

11:00 Swiss Biotech Success Stories Awards

Luca Bolliger, jury president

11:20 Celebrating 25 years of the Swiss Biotech Association

Cake Cutting Ceremony



Presented by   

11:45-12:30 Pitch

Room Singapore

Swiss Biotech Association Chapter: Lab Automation, Diagnostics and Analytics

Launch of a new Swissbiotech Association chapter evolving around laboratory sciences, automation, and the development of novel technologies and analysis pipelines for diagnostics and patient stratification, growingly powered by new possibilities stemming from digitalization and customized IT solutions. After a short introduction, we will host pitches of selected startups embedded in this lively ecosystem.

11:45 Introduction

Michael Altorfer, CEO, Swiss Biotech Association

Hans Noser, Managing Director, Toolpoint

Samantha Paoletti, Head of Research and BD Life Science Technologies, CSEM

11:55 Deep Breath Intelligence**12:00 Clemedi****12:05 Diaxxo****12:10 Accroma Labtec Ltd****12:15 Oncobit****12:20 Kugelmeiers Ltd****12:30-13:15 Panel Discussion**

Room Singapore

Lab automation and diagnostics beyond 2030

What is the very next future of lab automation and diagnostics like? Offering a very diverse point of view, our panelists will discuss the upcoming opportunities and challenges related to several key aspects: multidisciplinary, technological, collaborative and regulatory. The discussion and inputs will foster activities cues for the newly established Swiss Biotech Association chapter Lab Automation, Diagnostics and Analytics.

Moderation: Vincent Revol, Head of Research and BD-Life Science Technologies, CSEM

Panelists:

Alexandra Vallon Eberhard, Senior Director-CTO, Global Partnering, Roche Diagnostics

Petra Popp, Global Head of Service and Aftersales, TECAN

Christian Zwicky, CEO, Deep Breath Intelligence

Eva Pisa, Vice President, piMed Consulting AG

Global Village

Delegation of China

Participants: CEFC, HK Investment and development, CICC Capital, TigerMed, Hengrui Europe Biosciences AG, CanSinoBIO, Medicilon, Leman Biotech Lausanne SA

Presented by




Delegation of Canada

Government of Canada

Canada's Trade Commissioner Service promotes Canadian strengths in markets around the world. Working with partners across Canada and capitalizing on our network of trade commissioners in 160 cities, we help Canadian businesses grow with confidence and support global investors looking to expand in Canada with confidential, free-of-charge information and services, including sector-specific market intelligence, contact introductions, and site selection visit arrangements.

Participants: Government of Canada, AbCellera Biologics, Inc., Lumii Inc., Edesa Biotech Inc., Dalriada Drug Discovery, Genome Canada, CCRM / OmniaBio Inc., Centre for Commercialization of Regenerative Medicine, Genomics Canada, Invest in Canada, Trade Commissioner Service, Innovation, Science and Economic Development Canada

Presented by



Delegation of Taiwan

National Taiwan University

Located at the Tech Nation Taiwan, National Taiwan University possesses four leading Bio-related Colleges (Medicine, Life Science, Public Health, Agriculture and Bioresources). Two technologies, the saponin-based vaccine adjuvants and the first-in-class small molecule drug for prevention of corneal blindness, are highlighted at our booth. Moreover, delegates from National Biotechnology Research Park including Development Center for Biotechnology (7 products, 3 platforms displayed), BioHub and Taiwan Bio Industry Organization seek collaborative and investment opportunities.

Participants: National Taiwan University, Taiwan Bio Industry Organization, Development Center for Biotechnology, Onward Therapeutics, Europe-Taiwan Biotech Association

Presented by



Delegation of Spain

Asociación Española de BioEmpresas (AseBio)

AseBio, the Spanish Bioindustry Association, brings together and represents the interests of companies, associations, foundations, universities and technology and research centres that work in the field of biotechnology in Spain. Over the past 20 years, we have been working to bring about positive political and economic changes that foster and drive development of the Spanish biotechnology sector.

Participants: AseBio, Diversa, Grifols, ProtoQsar, BioBide, Affirma Biotech S.L., Arquimea, Pharmamar, Almirall, Halth in Code

Presented by



Delegation of Queensland

Trade and Investment Queensland

Queensland is home to a cluster of agile, innovative and entrepreneurial biomedical businesses. Our pre-clinical and early-phase clinical trial capabilities are underpinned by a world-class research base and state-of-the-art translational facilities.

Existing strengths and emerging capabilities include: vaccine development and delivery, biopharmaceutical contract manufacturing, microbiome analysis and development, immunotherapies, generic pharmaceuticals, clinical trials

Participants: Griffith University, Trade and Investment Queensland, Fraunhofer Institute for Toxicology and Experimental Medicine

Presented by



Delegation of Thailand

SCG

SCG is a leading business conglomerate in the ASEAN region. The company is expanding into Life Sciences and has created Nexter Ventures a dedicated Corporate Venture Capital unit to invest in life sciences technology at all stages. Our focus areas for investment and value creation in partnerships include Biologics CDMO, Genomics, Cell and Gene Therapy and Metabolic Therapies. We seek to help companies bring new technologies to the ASEAN region.

Participants: The Siam Cement PLC. (SCG), Siam Bioscience, Apexcela co. Ltd., Swiss Thai Chamber of Commerce STCC

Round Table Discussions











Please join us for roundtable discussions, aiming to facilitate partnerships and connect international representatives with the Swiss biotech industry for research, corporate collaborations, policy-making and investments.

Time	Country	Room San Francisco
11:30-12:00	Delegation of China	
12:15-12:45	Delegation of Canada	
13:00-13:30	Delegation of Taiwan	
13:45-14:15	Delegation of Spain	
14:30-15:00	Delegation of Queensland	
15:15-15:45	Delegation of Thailand	

Emerging Biotech Companies

Moderation: *Veronica Gambillara Fonck & Ximing Ding,*
Pureos Bioventures







Presented by **PUREOS**
BIOVENTURES

Time	Company	Room Sydney
12:30	NXI Therapeutics	
12:45	Stromal Therapeutics	
13:00	Adoram Therapeutics	
13:15	Onena Medicines	
13:30	Recolony	
13:45	Onward Therapeutics	
14:00	Nuclidium	
14:15	Tenpoint Therapeutics	
14:30	Somagenetix	
14:45	Healiva	

See all information on the presenting companies here →



Clinical Stage Companies

Time	Company	Room Rio
12:30	Stalicia	
12:45	Scandion Oncology	
13:00	InnoMedica AG	
13:15	Aurealis Therapeutics	
13:30	ETHRIS	
13:45	Alentis Therapeutics	














See all information on the presenting companies here →



Advanced Biotech Companies

Presented by



Time	Company	Room Osaka
12:30	Stücker Park	
12:45	ClearView Healthcare Partners	
13:00	Clinical Trial Consulting (CTI)	
13:15	Neo4j	
13:30	Quanterix	
13:45	Ardigen	
14:00	TETEC	
14:15	Elsevier B.V.	
14:30	Becton Dickinson	
14:45	Carl Zeiss	
15:00	BIOIVT	
15:15	Invest Hong Kong	
15:30	Mercuri Urval	

Presented by

**12:30-13:15 Panel 13**

Room Montreal

From bench to business – Steps to bring your development start-up to a commercial organization

Peter Mozerov and Caroline Chua from KPMG Switzerland will present the latest trends in European market access, regulatory and tax impacting life science start-ups, as well as explain their experiences and best practices for companies turning to commercial stage and launching products.

Panelists:

Caroline Chua, Senior Manager, Value Chain Management & Transfer Pricing, KPMG AG

Peter Mozerov, Senior Manager, Life Sciences Consulting, KPMG AG

Presented by

**13:30-14:15 Panel 14**

Room Montreal

Microphysiological systems and advanced 3D in vitro models as tools for innovating preclinical drug discovery

Drug development is known to be time consuming and very expensive. Pre-clinical studies are executed on animals to explore toxicity and pharmacology but often the responses are not accurate and do not perfectly reflect human physiology. The 3D in-vitro model is an innovating approach to accelerate drug development to predict toxicity and pharmacology using human cells. The panel will give an overview about the project and possible future applications.

Moderation: Dr. Giorgio Calderari, Chairman of Association Life Sciences, Innovation Park Ticino

Panelists:

Luca Bolzani, President, Fondazione Agire

Matteo Moretti, Regenerative Medicine Technologies Lab, Laboratories for Translational Research (EOC) & Faculty of Biomedical Sciences, Euler Institute, USI

Reto Naef, Founder and chairman of the board of directors, Topadur Pharma AG

Gionata Frasca, Co-Founder and Managing Director, CMC Pharmatech Sgl

Presented by

**14:30-15:15 Panel 15**

Room Montreal

Early involvement of regulators to deliver innovation to patients: Experience sharing by SWISSMEDIC Switzerland & ANVISA Brazil

Swissmedic in Switzerland and ANVISA in Brazil are internationally recognized regulators. They play a pivotal role in supporting Biotech R&D SMEs in their preparation of clinical trials and effective delivery of innovative and reliable therapies to patients. Regulators are interested in engaging with Biotech R&Ds at an early stage to increase the chances of complying with regulatory requirements. Swissmedic and ANVISA will discuss their experiences and present access points.

Moderation: Eliane Schmid, Head of Communications, Swissmedic

Panelists:

Philippe Girard, Vice-Director, Swissmedic

Antonio Barra Torres, Director, Brazilian Health Regulatory Agency ANVISA

Martin Kayser, Chief Technology Officer, Wyss Zurich Translational Center

Presented by

**15:30-16:15 Panel 16**

Room Montreal

Cell and Gene Therapy revolution – how can Switzerland stay at the forefront?

With the US and China running 90% of clinical CGT trials, the EU, UK and Switzerland risk to fall behind. Where are the opportunities and challenges for Switzerland to play an important role in this growing sector? How can the access to novel therapies be improved? How do we bring brilliant research and breakthrough therapies to the patient – what can be different in Switzerland? How can production and supply support, and do we need a more coordinated Swiss way?

Moderation: Dorothea Ledergerber, Chief Technical Officer, Tigen

Panelists:

Karin Blumer, Head of Corporate Affairs CHAT, Bristol Myers Squibb

Lana Kandalajt, Chief of Service of the Center of Experimental Therapeutics, Department of Oncology, CHUV-UNIL

Joerg Schlaepfer, Head of Management Services and International Affairs, Swissmedic

Vera Hirsch, Head of Claims Management Pharmaceuticals and Genetics, Sanitas

Roch-Philippe Charles, Chief Scientific Officer, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung SAKK

Presented by

**12:30-13:15 Panel 17**

Room Samarkand

Coming from abroad: What is it like to step into the Life Science industry in Switzerland?

Are you considering working in Life Sciences in Switzerland? Please join us as we explore the journeys of those who have taken this plunge! What is it actually like to move, live and work in Switzerland – the practicalities of obtaining a work permit, opening a Swiss bank account, finding a place to live, navigating the languages, and joining international teams across the spectrum of pharma companies. Also, insightful for attracting candidates from the global talent pool.

Moderation: *Christina Brewster-Maund, Sen. Director Resource Management and HR, CTC Resourcing Solutions*

Panelists:

Sara Okumu-Fransche, Medical Alliances Operation Leader, joining: Roche

Antonio Serrano Albarras, Clinical Operations Coordinator, joining: Idorsia

Egle Rugyte, Senior CRA, joining: Idorsia

Máté Sebesztha, Drug Safety Physician, joining: Actelion (JnJ)

Presented by

**13:30-14:15 Panel 18**

Room Samarkand

Talent in Biotech – How Switzerland shines?

Talent in Switzerland: moving from corporate to biotech and vice-versa. Which values talent needs to hold in biotech Switzerland. What are the best sources for talent in Switzerland? How to nurture computational talent in our Swiss entrepreneurial ecosystem.

Moderation: *Nathalie Rowell, CEO, VirdisGroup*

Panelists:

Patricia Jaquet, CPO, Ichnos Sciences

Laurence de Schouepnikoff, CEO, TridekOne

Amri Johnson, CEO, Inclusion Wins

Presented by

**14:30-15:15 Panel 19**

Room Samarkand

Venture Builders

We see more and more often that investors get educated about a technology and decide to build a biotech company from scratch. Why are investors ready to take the risks associated with early-stage companies? How much stamina is needed to get to the next level? How is venture building seen by follow-on investors? The panel tries to answer these questions.

Moderation: *Dani Bach, Partner, +ND Capital*

Panelists:

Karen Wagner, Partner, Ysios Capital

Daniela Couto, Partner, BioGeneration Ventures

Alexander Mayweg, Managing Director, Versant Ventures

Presented by

**15:30-16:15 Panel 20**

Room Samarkand

**Late-Stage Biotech –
Creating Value Through Business Development**

Experienced dealmakers discuss how to create value through business development in an adverse financing environment.

- Dr. Julian Jones is CBO at Monte Rosa, a clinical-stage company developing molecular glue degraders. At Eli Lilly, she previously worked on the \$8 billion acquisition of Loxo Oncology.
- Dr. Corinne Savill is CBO at Cullinan Oncology, a clinical-stage cancer therapeutics firm. She previously led Business Development and Licensing at Novartis Pharma.
- Dr. Jens Hennecke is CBO of Sotio Biotech, a clinical-stage immunotherapy company. He previously worked at Micromet on their \$1.2 billion acquisition by Amgen.

Moderation: *Chandra P. Leo, Investment Advisor, HBM Partners*

Panelists:

Julian Jones, Chief Business Officer, Monte Rosa Therapeutics

Corinne Savill, Chief Business Officer, Cullinan Oncology

Jens Hennecke, Chief Business Officer, Sotio Biotech



Presented by

12:30-13:15 Panel 21**Marriott Hotel****Microbiome – the emergence of a new treatment paradigm across a wide range of disease areas**

The microbiome is a rapidly advancing field. After a decade of research, the first microbiome-based products received market approval, opening up new commercial opportunities. This panel is designed as educational piece for a broad audience discussing true drug development in the field. Switzerland is a global leader in microbiome innovation, with world-class research institutions and companies driving progress in the field to develop new treatments.

Moderation: *Tomas de Wouters, PharmaBiome*

Panelists:

Gemma Henderson, Bacthera

Stefan Lutzmayer, IQVIA

Kristin Wannerberger, Ferring Pharmaceuticals

Simon Ittig, T3 Pharma

Presented by

**13:30-14:15 Panel 22****Marriott Hotel****Food for thought: trends in microbiome health-tech**

The microbiome health-tech industry provides a wide-range of interventions relevant to healthcare, including food & dietary supplements. The sector is evolving rapidly to become more scientifically proven. Microbiome-directed interventions are already in the clinic, where they are being used to help treat conditions like cancer & depression. The biopharmaceutical industry should be paying attention.

Moderation: *Marc Creus, CSO, plusbiome AG*

Panelists:

Tim Mak, EMEA Principal Scientist, DSM

Fabian Wahl, Member of the Board, Agroscope

Manuel Fankhauser, CEO, Seerave Foundation

Presented by

**14:30-15:15 Panel 23****Marriott Hotel****From early diagnosis to access to treatments for rare diseases – European and US perspectives**

The panel will discuss the particularities of developing and bringing new innovative medicines for rare diseases to the market and to patients. Speakers will present regulatory perspectives for orphan drugs in Europe and the US, as well as market access considerations in Europe with a focus on Switzerland and share the biotech perspective and particularities developing highly innovative products.

Moderation: *Nathalie Schober-Ladani, Senior Director Public Affairs and Regulatory Intelligence, SFL*

Panelists:

Anja Bühner, Vice President Regulatory Affairs and Deputy Head of the SFL Group, SFL

John Kirk, Principal Regulatory Strategist, Veristat

Anna Ulbricht, Senior Director Medical Affairs and Market Access, SFL

Charlotte Chanson, Senior Director Global Diagnostics / Newborn Screening, Orchard Therapeutics

Presented by

**15:30-16:15 Panel 24****Marriott Hotel****Speed to Clinic**

Speed is essential to progress therapeutic candidates from discovery to the clinic. Attaining key milestones as fast as possible is critical for biotech SMEs to make their candidate a success. Lonza and Biotech R&D SMEs will present experiences and discuss solutions aimed at overcoming typical challenges.

Moderation: *Dominik Wegmann, Head of MSAT Ibex Operations at Lonza*


Panelists:

Christoph Schäfer, CEO of CIS Pharma AG


Zoë Johnson, Chief Scientific Officer at Affivant Sciences GmbH

Floor Map

2nd floor



3rd floor



The **Marriott Hotel**, panel discussions 9-12 and 21-24, is located on the intermediate level between the entrance and the 2nd floor.

















- Exhibitor Booths
- Sessions
- Exhibitor Service
- Catering
- Coffeebike
- Poster presentations
- Global Village
- Partnering Tables
- Partnering Help Desk

Exhibitors

















Booth	Exhibitor
#1	Swiss Biotech Association 
#2	SBA & Friends  
#3	Suvoda LLC 
#4	Bio-Techne 
#5	SIX Swiss Exchange 
#6	Lexogen 
#7	PALL International 
#8	Cambrex 
#9	IMCD Switzerland 
#10	Biopôle 
#11	Citeline 
#12	ten23 health Valais 
#13	INDATECH (Chauvin Arnoux) 
#14	CROss Alliance 
#15	Porton Pharma Solutions 
#16	ACROBiosystems 

See all information on the exhibitors here →



















Booth	Exhibitor
#17	Novogene 
#18	Innosuisse 
#19	Deloitte 
#20	Envirotainer 
#21	SAKK 
#22	Caidya 
#23	Hamilton Bonaduz 
#24	PURNA Pharmaceuticals 
#25	CRB 
#26	IPS - Integrated Project Services 
#27	SGS Analytical Service Switzerland 
#28	YUMAB 
#29	KLIFO 
#30	PolyPeptide Group 
#31	AnaPath 
#32	SFL Regulatory Affairs & Scientific Communication 

Exhibitors

Booth	Exhibitor
#33	Beckman Coulter 
#34	ECO Swiss 
#35	Schrödinger 
#36	MyData-TRUST 
#37	Vector Builder 
#38	LubioScience 
#39	DHL 
#40	Eurofins Biopharma 
#41	BD (Becton Dickinson) 
#42	Sino Biological Europe 
#43	Tigermid 
#44	MECO 
#45	Remap 
#46	Emergent BioSolutions 
#47	Unilabs Serving Pharma 
#48	Advanced Clinical Switzerland 

See all information on the exhibitors here →



Booth	Exhibitor
#49	Raumedic 
#50	Valgenesis 
#51	ZETA 
#52	ProtaGene 
#53	DPS Group 
#54	Biotechnet Switzerland 
#55	CSEM 
#56	ExcellGene 
#57	Medicilon 
#58	Northway 
#59	Chemie Brunschwig 
#60	WuXi AppTec 
#61	Bionter 
#62	pqi Pharma Services 
#63	GXPManagers 
#64	Allucent 






Exhibitors

Booth	Exhibitor	
#65	ProPharma	
#66	BIOCOM	
#67	Miltenyi Biotec	
#68	Jacobs	
#69	LYO-X & iBiologix	
#70	Microsynth	
#71	Pharmadule Morimatsu	
#72	Stemcell	
#73	Selvita	

See all information on the exhibitors here →



Further Sponsors

Sponsor	
Comac Medical	
EuroScienceJobs	
Evidenze Health	
handshake	
ICON	
SOPHIA GENETICS	
Superlab Suisse	

Poster presentations

No.	Company	Room Singapore
#1	Vaccantis AG	
#2	Diaxxo	
#3	Alitheia Genomics	
#4	MesenFlow Technologies SARL	
#5	MV BioTherapeutics SA	
#6	NOVOCHIZOL SA	
#7	CIS Pharma AG	
#8	Pheida AG	
#9	Selmod GmbH	
#10	NexMR GmbH	
#11	Amazentis SA	

Registered Companies

(as of 13 April 2023)

- Member of Swiss Biotech Association

Company	Country	SBA-Member
2 BRIDGE	BE	
2bind GmbH	DE	
7AlpsBio GmbH	CH	•
AAC Infotray AG	CH	
AbbVie Deutschland	DE	
AbbVie Ventures	US	
abc biopply AG	CH	•
abcDNA GmbH	CH	•
AbCellera Biologics UK Ltd	GB	
ABF Pharmaceutical Services GmbH	AT	
ABIQUIFI - Brazilian Industry Association of Active Pharmaceutical Ingredient	BR	
ABL Europe	FR	
Abologix	CH	•
Absolute Antibody Ltd	GB	
Abzena	GB	
AC BioScience SA	CH	•
ACCELERATE SRL	IT	
Accella Advisors GmbH	CH	
ACROBiosystems AG	CH	•
ACTHERA THERAPEUTICS AG	CH	•
Acuvi GmbH	CH	
Adare Pharma Solutions	IT	
adesso Schweiz AG	CH	
Adiposs SA	CH	•
Adoram Therapeutics SA	CH	•
AdvanceCT	USA	
Advanced Clinical	CH / D / F	•
Advestra AG	CH	
Advisory and Technologies SA	CH	•
Aesara Europe GmbH	CH	
AFFIRMA BIOTECH S.L.	ES	
Affivant Sciences GmbH	CH	•
Agro-bio	FR	
Alentis Therapeutics AG	CH	•
Alessandro Di Domizio - SPILLOproject	IT	

Company	Country	SBA-Member
Alfasigma Schweiz AG	CH	
allpack group ag	CH	
Almac Group	GB	
Alpès Capital SA	CH	
ALTHEKIA	FR	
Amanda Penco	CH	
Amazon Web Services	CH	
Amphelix AG	CH	•
AMYRA BIOTECH AG	CH	•
AnaPath Services GmbH	CH	•
Ancillarie LLP	IN	
Andreas Wallnoefer Life Sciences Consulting	CH	
ANS Biotech SA	FR	
anteris helvetia	CH	•
Apexcela Co.,Ltd.	TH	
Aphaia Pharma AG	CH	•
Apricot Therapeutics AG	CH	•
Aragen Life Sciences	IN	
Araris Biotech AG	CH	•
Arcondis AG	CH	
Arctic Pharma AS	NO	
Arcturus Therapeutics	US	
Ardena Ghent	BE	
Ardena Södertälje AB	SE	
Ardigen	PL	
ARENSIA Exploratory Medicine GmbH	DE	
ariadne.ai ag	CH	
Ariane Mansouri Consulting	DE	
Ariceum International AG	CH	•
Aronora, Inc	US	
Arquimea Medical	ES	
ARTUS Unicon AG	CH	
ARXUM	DE / FR	
Asceneuron SA	CH	•
ASGENTO	DE	
Asociación Española de BioEmpresas (AseBio)	ES	
Asterivir AG	CH	
ASTRA Therapeutics GmbH	CH	•
Asyia Diagnostics BV	BE	
Athebio AG	CH	•

Company	Country	SBA-Member
ATLANTIC BONE SCREEN	FR	
Atum	US	
Aukera Therapeutics GmbH	CH	●
Aurealis Therapeutics AG	CH	●
Auregen Biotherapeutics SA	CH	●
Avance Basel GmbH	CH	●
AvogadroLS	FR	
AWP Finanznachrichten	CH	
Axon Lab AG	CH	●
AXXAM SPA	IT	
Azafaros Switzerland AG	CH	●
Azur Health Science SARL	FR	
Bachem AG	CH	●
BAG Health Care	DE	
BALIOPHARM AG	CH	●
bamconn GmbH	DE	
BASF SE	DE	
Batavia Biosciences BV	NL	
Bayer AG	DE	
BBD Biophenix S.L.	ES	
BC Platforms AG	CH	●
BECARV	BE	
Beckman Coulter Life Sciences	CH	
Becton Dickinson	BE / IT	
Benchling	CH	
Berlin Partner für Wirtschaft und Technologie GmbH	DE	
Bern Economic Development Agency	CH	
BERNINA BioInvest	CH	●
BigOmics Analytics	CH	●
Bio IVT	US	
Bio-Rad AbD Serotec GmbH	DE	
Bio-Techne	GB	
Bio-Technopark Schlieren-Zürich	CH	●
BioAgilytix	DE	
BioCentury Inc.	GB	
BIOCOM AG	DE	
Biocytogen Europe Innovation Center	DE	
BioDuro-Sundia	US	
Bioengineering AG	CH	●
BioFI AG	CH	

Company	Country	SBA-Member
Biofidus AG	DE	
BioGeneration Ventures	NL	
BioGenes GmbH	DE	
BioKryo GmbH	DE	
BioLAGO e.V.	DE	
Biolytix AG	CH	
Biomapas UAB	LT	
BioMedPartners AG	CH	●
Bionter AG	CH	●
Biopôle SA	CH	●
BioRN Cluster Management GmbH	DE	
biosaxony Management GmbH	DE	
Bioscience Valuation BSV GmbH	DE	
BIOSPHERE SRL	IT	
Biosynth AG	CH	●
Biotechnet Switzerland	CH	
BIOTYPE GmbH	DE	
BioValley Basel Association	CH	
BioVersys AG	CH	●
Bitlums	CH	
Blau Farmaceutica	BR	
blsc - bihlmann life science communication	CH	●
BlueClinical - Investigação e Desenvolvimento em Saúde, Lda.	PT	
BOC Sciences	US	
Boehler Life Science Advice	CH	●
Bolders Consulting Group	CH / NL	
Botschaft des Königreichs der Niederlande	CH	
Brazilian Pharmaceutical Innovation Network - RBIF	BR	
BRIM Biotechnology, Inc.	TW	
BRIM Taiwan	HK	
Bristol-Myers Squibb SA	CH	
BROTHERS & Partners Europe	FR	
BSI Business Systems Integration AG	CH	
BSSE-ETHZ	CH	
BWT AQUA AG	CH	
C/Can · City Cancer Challenge	CH	
Caidya	US	
CAMARA DE COMERCIO DE SANTIAGO	ES	
Cambrex Corporation	US	
Campus SLB Sonnenhof AG	CH	

Company	Country	SBA-Member
Cancer Research and Biotechnology AG	CH	●
CanSino Biologics Switzerland SA	CH	●
Canton of Zurich, Business and Economic Development	CH	
CanVirex	CH	●
CARBOGEN AMCIS Innovations AG	CH	●
Carl Zeiss AG	CH	
Carl Zeiss Microscopy GmbH	DE	
Catalent Pharma Solutions	CH	●
Catalyze Group B.V.	CH	●
Catenion GmbH	DE	
Cavenagh Health	GB	
CDR-Life	CH	●
Celerion Switzerland AG	CH	●
Cellbox-Solutions GmbH	DE	
Cellestia Biotech AG	CH	●
Cellis AG	CH	
Celonic AG	CH	●
Centre for Commercialization of Regenerative Medicine	CA	
Cerbios-Pharma SA	CH	●
Cetacea Consulting GmbH	CH	●
Chaberton Partners	CH	
Changchun GeneScience Pharmaceutical Co. Ltd	CN	
Charité Research Organisation GmbH	DE	
Charles River Laboratories	DE / FR / IT	
Charnwood Molecular Ltd	GB	
Chemengineering Switzerland AG	CH	●
Chemie Brunschwig AG	CH	
Chinsiders GmbH	CH	●
Choose Life Biotech SA	CH	●
Chromatographic Technologies	CH	
CICC Capital	CN	
CILATUS BIOPHARMA CONSULTING AG	CH	●
CILOA	FR	
CIS Pharma AG	CH	●
Citeline	GB	●
CK Group	GB	
CK QLS AG	CH	
CLARIO	CH	
Claus Hemker	DE	
CLEAN CELLS	FR	

Company	Country	SBA-Member
ClearView Healthcare Partners	CH	●
Clemedi AG	CH	●
Clinical Research Services Turku-CRST	FI	
Clinigen Clinical Supplies Management SA	BE	
Clinmark Sp. z o.o.	PL	
ClinOps Advisory Turner GmbH	CH	●
Clinscience	PL	
CMC Pharmatech Sagl	CH	
CNRS INEM UMR7355	FR	
Comac Medical Ltd	BG	
Commissioning Agents International	CH	
Concept Life Sciences Limited	GB	
Convex Phase I unit	BG	
Coopers Group AG	CH	
Corden Pharma International GmbH	DE	
Coriolis Pharma Research GmbH	DE	
Cork County Council	IE	
Coulter Partners	CH	●
CRB Group GmbH	CH / DE	●
Croda GmbH	DE	
CROSS Research SA	CH	●
CRS Clinical Research Services Management GmbH	DE	
CSEM SA	CH	●
CSL Vifor AG	CH	●
CTC Resourcing Solutions AG	CH	●
CTI Clinical Trial & Consulting	US	
Cullinan Oncology	US	
Culture Collection of Switzerland AG	CH	●
Curare Swiss AG	CH	●
CURIA	US	
Curia Global Inc	US	
Curio Biotech SA	CH	●
CUTISS AG	CH	●
CVO-EUROPE	CH	
Cynbiose	FR	
Cytiva Europe GmbH	CH	●
Cyxone AB	SE	
D_CoRe	CE	
Dalriada Drug Discovery	CA	
DataArt Consulting GmbH	CH	

Company	Country	SBA-Member
DataHow AG	CH	
Debiopharm International SA	CH	●
DEBIOTECH SA	CH	
Deep Breath Intelligence AG (DBI)	CH	●
Deloitte	CH	
DELPHARM	FR	
Department of Innovative Technologies University of Applied Sciences and Arts of Southern Switzerland	CH	
Design Pharmaceuticals	US	
Development Center for Biotechnology	TW	
DHL Express (Schweiz) AG	CH	
DIA Drug Information Association	CH	
Diaxo AG	CH	●
Digibooster Sàrl	CH	
Digital Innovation Partner	CH	
Digital Lab Consulting	GB	
digitalswitzerland	CH	
DIPHARMA FRANCIS	IT	
DIVERSA Technologies S.L.	ES	
Domainex Ltd	GB	
Dottikon Exclusive Synthesis AG	CH	
DPS Group	CH	●
DrM, Dr. Mueller AG	CH	●
DyNABind GmbH	DE	
Dynamk Capital	US	
ECO SWISS	CH	
ECOLE POLYTECHNIQUE DE LAUSANNE (EPFL)	CH	
Edesa Biotech Inc.	CA	
EffRx Pharmaceuticals SA	CH	●
Egon Zehnder International	CH	
Element Materials Technology	GB	
eleva GmbH	DE	
Elsevier B.V.	NL	
Elthera AG	CH	●
Embassy of Canada to Switzerland and Liechtenstein	CH	
Emergent BioSolutions	US	
Emergent Biosolutions Berna GmbH	CH	●
Encentrio Therapeutics International GmbH	CH	●
Endogena Therapeutics Inc	CH	●
enGenes Biotech GmbH	AT	

Company	Country	SBA-Member
Entegris	FR	
ENVIROTAINER	SE	
EPFL Innovation Park	CH	
EQT Partners GmbH	DE	
EraCal Therapeutics	CH	●
Ernst & Young AG	CH	
ETH Zurich & University of Bern	CH	
Ethris GmbH	DE	
Euresearch Basel	CH	
Eurofins Amatsigroup SAS - CFR175	FR	
Eurofins BioPharma Product Testing Munich GmbH	DE	
EuroJobSites Ltd	GB	
Europe-Taiwan Biotech Association	CH	
European Circular Bioeconomy Fund	DE	
European Pharmaceutical Students' Association	PT	
Evaluate Ltd	GB	
EVEON	FR	
Eversana LLC	US	
EVIDENT Europe GmbH	DE	
EVIDENZE EUROPE S.L.	ES	
Evidenze Health España S.L.	ES	
Evir therapeutics	CH	
evitria AG	CH	●
Evolve AG	CH	
Evonik Operations GmbH	DE	
Excella GmbH & Co KG	DE	
ExcelGene SA	CH	●
Excelya	FR	
Expertinova AG	CH	●
Exsegen Genomics Research Private Limited	IN	
F. Hoffmann-La Roche AG	CH	●
FABLE GmbH	CH	●
FAREVA CORPORATE FRANCE	FR	
Fareva Deutschland GmbH	DE	
FARMHISPANIA GROUP, S.L.	ES	
Fatiabgen	KR	
FB Global Regulatory Consulting and Coaching	CH	
FCDO	GB	
Ferring Pharmaceuticals	CH	
FGK Clinical Research GmbH	DE	

Company	Country	SBA-Member
FHNW	CH	
FimmCyte AG	CH	
Finanz und Wirtschaft / Tamedia	CH	
Fischer PreclinTox Consulting	CH	●
Flanders Investment & Trade Zurich	CH	
Floratek Pharma SA	CH	●
Fondazione Agire	CH	
FONGIT - Fondation Genevoise pour l'Innovation Technologique	CH	
Forbion	NL	
FoRx Therapeutics AG	CH	
Frank W Lee	US	
Fujifilm France	FR	
Full scale bioinformatics	NL	
Future Health Pharma GmbH	CH	●
G & U Job4You GmbH	CH	
G&L Scientific Ltd	UK	
Galapagos GmbH	CH	●
GalChimia, S.A.	ES	
GALSER SA	CH	●
GBC-HpVac SA	CH	●
GEM	US	
General Inception	US	
GeNeuro SA	CH	●
Genius Search GmbH & Co. KG	DE	
GENOPOLE	FR	
GenScript Biotech (Netherlands) B.V.	NL	
Giblot Food and Health GmbH	CH	●
GIE Eurasanté	FR	
GliaPharm SA	CH	●
Global Affairs Canada	CA	
Global Emerging Markets Group	US	
GMP-Verlag Peithner AG	DE	
Google LLC	CH	
Government of Canada	CH	
Greater Geneva Bern area	CH	
Griffith University	AU	
Griffon Pharmaceuticals International SA	CH	●
Grifols	ES	
Guidance	IND	
GXP CONSULTING Switzerland	CH	●

Company	Country	SBA-Member
GxpManager	FR	●
HAMILTON BONADUZ AG	CH	
Handelskammer Deutschland Schweiz	CH	
handshake Handelsges.m.b.H.	AT	
Hangzhou Tigermed Consulting Co.,Ltd	CN	
Haselmeier GmbH	DE	
HAYA Therapeutics	CH	●
HBM PARTNERS	CH	●
Healiva SA	CH	●
Health Advances LLC	CH	●
HEALTH IN CODE, S.L.	ES	
HealthEcon Ltd	DE	
Helbling Technik Wil AG	CH	
Helsinn Healthcare SA	CH	●
Hemex AG	CH	●
HemostOD SA	CH	●
Hengrui Europe Biosciences AG	CH	●
HES-SO Valais-Wallis	CH	
Histocell, S.L.	ES	
Hobson Prior	GB	
Hoffmann & Partner AG	CH	
Homburger AG	CH	●
House of Lab Science	CH	●
Hovione Farmaciencia SA	PT	
HTCR Services GmbH	DE	
Humabs BioMed SA	CH	●
HungaroTrial CRO	GB	
hVIVO Services Ltd	GB	
Hyperbolic Holdings GmbH	CH	●
Iama Discovery Solutions	GB	
IBSA Institut Biochimique SA	CH	
Ichnos Sciences SA	CH	●
ICON	DE/ ES / HU	
ICON Clinical Resaerch LLC	US	
ICROM SRL	IT	
IDDI (International Drug Development Institute) SA	BE	
Idorsia Pharmaceuticals Ltd.	CH	●
IE Life Science Engineering	CH	●
IHMA Europe	CH	
ILCPharma Treinamentos e Assessoria Ltda	BR	

Company	Country	SBA-Member
ImaBiotech & Pyxant Labs	FR / US	
IMCD Switzerland AG	CH	
IMG - Investitions- und Marketinggesellschaft Sachsen-Anhalt mbH	DE	
Immunophotonics / IPS Biopharma AG	CH	●
INCAPTEK Sàrl	CH	
InCephalo AG	CH	●
Inclusion Wins bei A Johnson Partners	CH	
INDATECH CA	FR	
Infinity Communications SARL	CH	
infoteam Software AG	CH	
InkVivo Technologies AG	CH	●
InnoMedica Switzerland AG	CH	●
Innomedical technology AG	CH	
InnoSer België NV	BE	
Innosuisse	CH	
Innovative Sensor Technology IST AG	CH	●
Innovaud	CH	
INOFEA AG	CH	●
INOVATIE CONSULTORIA E SERVIÇOS EM SAÚDE LTDA	BR	
INOVATIE SERVIÇOS EM SAÚDE	BR	
inSEIT AG	CH	
InsideReg Sàrl	CH	●
InSilicoTrials Technologies SPA	IT	
Institute for Genetic and Biomedical Research – Consiglio Nazionale delle Ricerche	IT	
Institute of Anatomy, University of Bern	CH	
Institute of Medical Microbiology	CH	
Integrated Biologix GmbH	CH	●
InterAx Biotech AG	CH	●
International Flavors & Fragrances - IFF [Solae Europe Sarl]	CH	
Interpharma	CH	
Intrials Clinical Research	BR	
Invasight AG	CH	●
InvestHK	DE	
InVivo Biosystems	US	
IPS - Integrated Project Services GmbH	CH / DE	●
Ipsen	FR	
iQone Healthcare Switzerland SA	CH	●
IQVIA	AT / CH / FR	
IRB Institute	CH	
Iron Bridge – CRO and LAB Consulting	DE	

Company	Country	SBA-Member
Isospec Analytics SA	CH	●
Ivarsson Consulting GmbH	CH	
Jeito Capital	FR	
K&S Partners	IN	
KELVINCOLE	NG	
Kemwell Biopharma Private Limited	IN	
Kisco sarl	CH	●
KLIFO	DK	
KPMG AG	CH	●
Kreos Capital	GB	
KYMOS S.L.	DE	
Labcorp Clinical Development Limited	DE	
Labcorp Drug Development	ES	
Lactocore Inc.	US	
Laevoroc Oncology AG	CH	●
LAGOSTA SA	CH	●
LAMBDA-X	BE	
LaRive Bio AG	CH	●
Laurus Synthesis	US	
Le Temps	CH	
leadXpro AG	CH	●
Leman Biotech Lausanne SA	CH	●
Leukocare AG	DE	
Lexogen	AT	
Libervinea	CH	
Life Science Medics	GB	
Life Science Zurich Young Scientist Network	CH	
Life Sciences Executive Search LLC.	CH	●
LIFENCY: a division of Com&Co Sagl	CH	
Lilly	CH	
LimmaTech Biologics AG	CH	●
Limula SA	CH	●
LINK Medical Research	NO / SE	
lino Biotech AG	CH	●
LionRock Capital Private Equity	HK	
Lonza AG	CH	●
LubioScience GmbH	CH	●
Lumio Inc.	CA	
Lumis International GmbH	DE	
Lynx Financial	CH	

Company	Country	SBA-Member
M&G Advisors GmbH	CH	
MabDesign	FR	
Mabylon AG	CH	
Macfarlan Smith Limited	GB	
MAGNA SOURCING INTERNATIONAL DISTRIBUTION AND SERVICES LTD.	BR	
marcommotion	DE	
Maruho Co., Ltd.	JP	
Maruho Deutschland GmbH	DE	
Maxia Strategies, LLC - , BASEL	CH	●
MBM Future Health	DE	
MD Bioproducts GmbH	CH	●
Med Discovery SA	CH	●
Medexpansion SaRL	CH	●
Median Technologies	FR	
Medicines Patent Pool	CH	
Medicon Valley Alliance	DK	
Medpace	US	
Merck Chemicals GmbH	DE	
Metabolon Inc	US	
MetrioPharm AG	CH	●
MGME Neurotech	CH	
Microsynth AG	CH	●
Midas Pharma GmbH	DE	
Miltenyi Biotec B.V. & Co. KG	DE	
MLM Medical Labs GmbH	DE	
Molecular Partners AG	CH	●
Monte Rosa Therapeutics	CH / US	●
Moonlight AI GmbH	CH	●
MORGAN PHILIPS SWITZERLAND	CH	
Morimatsu Italy S.R.L.	IT	
MPC Therapeutics	CH	●
MPGassen DMPK Consulting	CH	
MRGBN Advisors	CH	●
MRL Consulting Group	GB	
msg industry advisors ag	DE	
MV BioTherapeutics SA	CH	●
MyData-TRUST SA	BE	
Myonex GmbH	DE	
Nagi Bioscience SA	CH	●
Nanobacterie	FR	
Nanobot OÜ	EE	

Company	Country	SBA-Member
NanoDimension AG	CH	
Nanoform Finland Oyj	FI	
Nanome Inc.	US	
NanoTemper Technologies GmbH	DE	
National Taiwan University	TW	
Navignostics AG	CH	●
Nawah Scientific	EG	
NBE-Therapeutics AG	CH	●
NCMA Consulting GmbH	CH	●
NDA Regulatory Service Switzerland GmbH	CH	●
Nebion AG	CH	
NEMIS Technologies AG	CH	●
Neo4j Germany GmbH	DE	
Neuland Laboratories Ltd	IN	
Neurimmune AG	CH	●
NewBiologix SA	CH	●
Nexco Analytics Sarl	CH	●
Nexo Science AG	CH	
NIMGENETICS GENOMICA Y MEDICINA S.L.	ES	
NIMGenetics SL	ES	
NovaGo Therapeutics AG	CH	●
Novartis	CH	●
Novigenix SA	CH	●
Novochizol SA	CH	●
NOVOGENE NETHERLANDS B.V	NL	
Novotech	AU	
Nubilaria srl	IT	
Nucleate	CH	
Nuclidium AG	CH	
Numab Therapeutics	CH	●
NUVISAN ICB GmbH	DE	
ObvioHealth	US	
obvioTec	CH	
OCCIDENT	CH	●
Olink Proteomics GmbH	DE	
Olon SpA	IT	
OM Pharma	CH	●
OMNI Life Science	CH	●
OmniaBio Inc., a Subsidiary of CCRM	CA	
Oncodesign Services	FR	●

Company	Country	SBA-Member
Onena Medicines AG	CH	●
Ontotext, SIRMA AI JSC	BG	
Onward Therapeutics SA	CH	●
OPIS	IT	
oprandi & partner sa	CH	●
Optimapharm	RS	
Optimapharm	HU	
Orchard Therapeutics	CH	
Oregon Bioscience Association	US	
Oregon Business Development Department aka Business Oregon	US	
Orio Therapeutics SA	CH	●
Orion Biotechnology Switzerland	CH	●
Orphan Drug Consulting	IE	
OST – Eastern Switzerland University of Applied Sciences	CH	
Otten Life Sciences Consulting sàrl	CH	●
P&TS SA	CH	
PALL INTERNATIONAL SALR	CH	●
Pattern Computer Inc	US	
PCAS	FR	
PCI Pharma Services	GB	
PDC FZ LLC	AE	
PDC Therapeutics S.A.	CH	●
Perseo pharma AG	CH	●
Pestalozzi Attorneys at Law	CH	
PHARALL GmbH	DE	
pharm-analyt Labor GmbH	AT	
Pharm-Olam Intl	GB	
Pharma Intelligence UK Limited – Company code Z014	GB	
PharmaBiome AG	CH	●
PharmaBoardroom	GB	
Pharmaron Ltd	DE /GB	
Pharminisight AG	CH	
Pheida AG	CH	●
Phoenix Clinical Research	LB	
Pilatus Biosciences SA	CH	●
Piramal Pharma Solutions	US	
plusbiome	CH	●
PLX Healthcare Services	CH	●
PMS Process Management System	CH	●
Polypeptide Laboratories Sweden AB	SE	

Company	Country	SBA-Member
Porton Pharma Solutions	CH	
Porton Pharmaceutical Chemicals GmbH	CH	
PPD Thermo Fisher	IE	
Pracipio Ltd	GB	
Praed Pharmaceuticals Ltd	CH	●
PreciHealth SA	CH	
Pretium Strategy	B	
Priavoid GmbH	D	
Princeton Capital Advisors LLC	USA	
PrJSC Enzym Company	UA	
ProBioGen AG	DE	
Procam Videoproduktionen David Prochazka und Josef Zeis	CH	
Promega AG	CH	●
ProPharmaGroup GmbH	DE	
ProtaGene GmbH	DE	
ProtoQSAR 2000 SL	ES	
Provectis Healthcare AG	CH	●
PSI CRO	CH	●
Pureos Bioventures	CH	●
Purna Pharmaceuticals NV	BE	
Purple Biotech GmbH	CH	●
PUXANO BV	BE	
Q4BS GmbH	CH	
Qanatpharma AG	CH	●
QBDC GmbH	CH	●
Qiáo Advisors GmbH	CH	●
Quant Biomarkers	CH	
Quanterix	USA	
Quartz Bio SA	CH	●
Quotient Sciences Ltd.	GB	
RAMBAM AG	CH	●
Raumedic AG	CH / DE	
Raybow PharmaScience APS	DE	
RD-BIOTECH	FR	
Receptor.AI, Ltd.	GB	
Reconnect Labs AG	CH	●
Referat 8310 Außenwirtschaft, Ministerium für Wirtschaft, Verkehr, Landwirtschaft und Weinbau	DE	
Regulatory Pharma Net Srl	IT	
Relate Science Ltd	GB	

Company	Country	SBA-Member
Remap Consulting GmbH	CH	●
RENTSCH PARTNER Ltd.	CH	
Resea Biotec GmbH	CH	●
Research magazine Horizons from the Swiss National Science Foundation	CH	
RespAct GmbH	CH	●
Rewire Neuro, Inc.	US	
Risklick	CH	●
Rivia SA	CH	●
Rockwell Automation Switzerland GmbH	CH	
Ropes & Gray	GB	
ROTRONIG AG	CH	
Rowestil Consulting GmbH	CH	●
RSA Group	CH	●
RUI REN	CH	
Sachs Associates Switzerland AG	CH	
Sai Life Sciences Limited	GB	●
Sanisure GmbH	DE	
Santhera Pharmaceuticals AG (Schweiz)	CH	●
Sanyou biopharmaceuticals	CN	
SARTORIUS	FR	
Sartorius Stedim Biotech GmbH	DE	
Sartorius Stedim Switzerland AG	CH	●
Saxony Trade & Invest	DE	
Scaillyte AG	CH	●
Scandion Oncology A/S	DK	
Scendea Ltd	GB	
SCHOTT Pharma Schweiz AG	CH	
Schrödinger GmbH	DE	
Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK)	CH	
Science. People. Business.	CH	
scienceindustries	CH	
Seagen	CH	●
Sebastian Gensior	CH	
Securecell AG	CH	●
SEED Biosciences SA	CH	●
Selexis SA	CH	●
Seqera Labs	ES	
Service de l'Économie de Neuchâtel	CH	
SFL Regulatory Affairs & Scientific Communication GmbH	CH	●
SGS	CH	●

Company	Country	SBA-Member
SGS	FR	
SGS Activos S.L.	ES	
SGS Analytics Switzerland AG	CH	●
SGS Institut Fresenius Diagnostiklabor GmbH	AT	
SGS NV	BE	
SGS Quay Pharmaceuticals	GB	
Shanghai Medicilon Inc	CN	
Shenzhen Dawu Venture Capital Co., Ltd.	CN	
Shilpa Medicare Limited	IN	
Shimadzu Schweiz GmbH	CH	
Siam Bioscience Co., Ltd	TH	
SICPA	CH	●
Sidrapex Pte Ltd	CH	
Simbec-Orion	GB	
Sindusfarma	BR	
SINDUSFARMA – Sindicato das Indústrias de Produtos Farmacêuticos	BR	
Sinergetica	IT	
Singleron Biotechnologies GmbH	DE	
Sino Biological Europe GmbH	DE	
SIRION Biotech SAS	FR	
Sirma AI Ad	BG	
Siron bv	NL	
Sitem StartUp Club	CH	
sitem-insel AG	CH	
SIX Swiss Exchange Ltd	CH	
SK pharmteco	IE	
Sodha Pharma Consulting GmbH	CH	
Solid Drug Development SA	CH	
Solvias AG	CH	
SOMAGENETIX AG	CH	●
SOPHIA GENETICS SA	CH	●
Sotio Biotech AG	CH / CZ	●
South Carolina Europe Office	DE	
SP Groups SA	CH	●
Specific Pig SI (Specipig)	ES	
SPLaw Advogados	BR	
Springer Nature	DE / GB	●
Springer-Verlag GmbH	D	●
STALICLA SA	CH	●
Stämm Vegh	AR	

Company	Country	SBA-Member
Standortförderung Basel-Stadt	CH	
Startupticker.ch	CH	
State of Valais – Office of Economy, Tourism and Innovation	CH	
STC Studio	CH	
STEMCELL Technologies	DE / FR	
Stemmatters - Biotechnologia e Medicina Regenerativa S.A	PT	
Sterling Pharma Solutions	GB	
StratiCELL	BE	
Streefkerk Life Sciences Consultancy (SLSC)	CH	●
Sulista Consulting	CH	
Supply Chain Operations SA	CH	●
Suvoda	US	
SwAPP	CH	
Swati Spentose Pvt Ltd	IN	
SwedenBIO	SE	
Swiss Biotech Association	CH	●
Swiss Biotech Center SA	CH	●
Swiss Consultant-Network GmbH	CH	●
Swiss Federal Institute of Intellectual Property	CH	
Swiss HLG	CH	
Swiss Indian Chamber of Commerce	CH	
Swiss Thai Chamber of Commerce	TH	
swissinfo.ch (SRG)	CH	
Swissmedic Swiss Agency for Therapeutic Products	CH	
SwisSolution Human Capital AG	CH	●
Switzerland Global Enterprise	CH	●
Switzerland Innovation	CH	
Symbiosis Pharmaceutical Services ltd	GB	
Synendos Therapeutics AG	CH	●
Syneos Health	CH / GB	●
Synexa Life Sciences	NL	
T3 Pharmaceuticals AG	CH	●
Taiwan Bio Industry Organization	TW	
Talisto GmbH	CH	●
Tanner Pharma CH GmbH	CH	
Tanner Pharma Group	US	
TargImmune Therapeutics AG	CH	●
Tebu-bio GmbH	DE	
Technologiepark Basel AG	CH	
Telluris Biotech India Pvt. Ltd	IND	

Company	Country	SBA-Member
Telomium	FR	
ten23 health AG	CH	●
Tenpoint Therapeutics GmbH	CH	●
The Puzzle	CH	
THE SIAM CEMENT PUBLIC COMPANY LIMITED	TH	
The University of Sheffield	GB	
Theradex (Europe) Ltd	GB	
TheraVenture GmbH	CH	
Thermo Fisher Scientific Biologics Lengnau	CH	●
Thermo Fisher Scientific	CH	
Thor Companies Ltd	GB	
ti&m AG	CH	
Tianjin Innomedical Technology Co., Ltd.	CN	
Tigermud Swiss AG	CH	●
TiVentures SA	CH	
Tjoapack Netherlands B.V.	NL	
TK Analytics Ltd.	SI	
TMC SCIENCE & TECHNOLOGY NV	BE	
TNO	NL	
TOLREMO therapeutics AG	CH	●
Topadur Pharma AG	CH	●
Trade and Investment Queensland	DE / FR	
TRAFIK Productions Ltd	GB	
TrendMD LLC	US	
trenzyme GmbH	DE	
Trial Form Support S.L.	ES	
Trialbee AB	SE	
Tridek-One Therapeutics SAS	CH	●
Trillome GmbH	CH	●
TS Kommunikation	CH	
tuari-therapeutics	DE	
Twist Bioscience Corporation	US	
UAB Biotechpharma	LT	
UbiVac Inc	US	
UBS Switzerland AG	CH	
UCB	CH	●
UFAG Laboratorien AG	CH	
Unilabs	DK	
Università della Svizzera italiana (USI)	CH	
Universitätsklinik Balgrist	CH	

Company	Country	SBA-Member
University of Applied Sciences Northwestern Switzerland	CH	
University of Bern Platform for Stem Cell Research and Regenerative Medicine (SCRM)	CH	
University of Zurich	CH	
UPC – UNION PHARMACEUTIQUE CONSTANTINOISE	DZ	
UPS Healthcare	CH	●
USI – Università della Svizzera italiana	CH	
UZH	CH	
Vaccentis AG	CH	●
Vaderis Therapeutics AG	CH	●
ValGenesis EMEA, B.V.	GB	
valuationLAB AG	CH	●
Vandria SA	CH	●
Vaudaux-Eppendorf AG	CH	
VectivBio AG	CH	
Vector BioPharma AG	CH	●
VelaLabs GmbH	AT	
VENAIR IBÉRICA S.A.U.	ES	
Venture Valuation VV AG	CH	●
Verein Toolpoint for Lab Science c/o Unitreva AG	CH	●
Veristat LLC	US	
Versameb AG	CH	●
Versant Ventures	CH	
Vetter Pharma International GmbH	DE	
Vifor (International) AG	CH	●
VLS Switzerland GmbH	CH	●
Viopas Venture Consulting GmbH	CH	●
vips	CH	
Vir Biotechnology	US	
Vir Biotechnology International GmbH	CH	●
VirdisGroup	CH	●
Virometix AG	CH	●
Virtual Nomad	US	
VIRUSURE GMBH	AT	
VISCHER AG	CH	●
Vivotecnia Research, S.L.	ES	
Voisin Consulting CH Sarl	CH	●
WWR (part of Avantor)	NL	
Walder Wyss AG	CH	●
Wallinger Ricker Schlotter Tostmann, Patent- und Rechtsanwälte	DE	
Watson-Marlow AG	CH	●

Company	Country	SBA-Member
Wemedoo AG	CH	
Wobatech	CH	
Worldwide Clinical Trials	ES / GB	
WuXi AppTec UK Ltd.	GB	●
WuXi Biologics	CN	●
Wyss Zurich ETH Zurich & University of Zurich	CH	●
Xcenda	CH	●
Xlife Sciences AG	CH	●
Yeditepe University	TR	
Ymmunobio AG	CH	●
Yokogawa Innovation Switzerland GmB	CH	●
YPrime LLC	USA	
YSIOS CAPITAL PARTNERS S.G.E.C.R., SA	E	
YugaCell GmbH	CH	●
YUMAB GmbH	DE	
ZETA AG CH	CH	●
Zühlke Engineering AG	CH	
Zurich University of Applied Sciences (ZHAW)	CH	
Zymvol Biomodeling S.L.	ES	

A BIG THANK YOU TO OUR SPONSORS!



Sponsors:



Supporting partners:



Media partners:



Organized by:



Save the date!

SWISS BIOTECH DAY 2024

© Swiss Biotech Association

April 22-23, 2024
Congress Center Basel

Are you interested in increased visibility at the next Swiss Biotech Day?

We offer various sponsorship opportunities designed to promote your brand, products, services and build partnerships.

Contact us to discuss your ideas!

Meet our team today here at the BIOCOM booth #66.

Or you can contact us at marketing@biocom.de.

Organized by: